Paradigm Biopharmaceuticals Advances Clinical Programs
Company Announcements

Paradigm Biopharmaceuticals Advances Clinical Programs

Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.

Paradigm Biopharmaceuticals Ltd. reported significant progress in their Phase 3 Osteoarthritis program after meeting with the US FDA and submitting response documents for review, welcomed a new Non-Executive Director, Matthew Fry, and announced successful Phase 2 trial results for their MPS VI study, showing safety and promising clinical improvements. The company also noted a substantial R&D tax refund of $7.3m and a decrease in quarterly R&D expenditure, with a current cash balance of $26.2m.

For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskParadigm Biopharma Advances Phase 3 Trials Amid Financial Prudence
TipRanks Australian Auto-Generated NewsdeskParadigm Biopharmaceuticals Advances Phase 3 Trial Plans
TipRanks Australian Auto-Generated NewsdeskParadigm Biopharmaceuticals Plans New Securities Issuance
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App